NIDA CRADA with Reckitt & Colman Pharmaceuticals
Executive Summary
The National Institute on Drug Abuse is contemplating a CRADA with Richmond, Va.-based Reckitt & Colman Pharmaceuticals to license sublingual dosage forms of buprenorphine -- in combination with naloxone or alone -- for the treatment of opiate dependence, May 12 Federal Register notice states. Reckitt & Colman markets the opioid analgesic Buprenex (buprenorphine) injectable for the relief of moderate to severe pain.